Endocrinological evaluations of a 48-year-old manwith Fabry disease revealed low levels of serum thyroid hormones and high levels of serum thyrotropin (TSH), indicating that the patient had primary hypothyroidism. Also, an exaggerated growth hormone (GH) response to hypoglycemic stimuli was observed. Thin layer chromatography of the lipid extract of the thyroid gland obtained by biopsy demonstrated marked accumulation of ceramide trihexoside (CTH) and ceramide dihexoside (CDH). These findings strongly suggest that thyroid hypo function and hypothalamic dysfunction could be involved in Fabry disease. (Internal Medicine 33: 172-176, 1994) 
Introduction
Fabry disease is an X-linked inborn error ofglycosphingolipid metabolism, characterized by the systemic accumulation of the glycosphingolipid substrate, ceramide trihexoside (CTH) and ceramide dihexoside (CDH) (1) . The cause of the disease is a deficiency of the specific oc-galactosidase enzyme,ceramide trihexosidase, which normally catalyzes the hydrolysis of the terminal oc-linked galactosyl residue in ceramide trihexoside (2) . Kint has shown that oc-galactosidase is deficient in the leukocytes of patients with Fabry disease (3) . In hemizygous males and some heterozygous females, CTHis deposited in the skin, kidneys, vasculature, and heart. Because of the widespread visceral distribution of the glycosphingolipid deposits, signs and symptoms of this disorder develop in many other organs and systems. It is characteristic that patients die during the fourth or fifth decade as a result of cardiac, cerebrovascular, or renal involvement (4) (5) (6) (7) (8) (9) . Although the involvement of the myocardium, kidney, and small blood vessels has long been recognized, endocrine disorder, particularly thyroid dysfunction has been rarely reported. Recently, we studied a 48-yearold man with Fabry disease, who had primary hypothyroidism. Laboratory data on admission (Table 1) were as follows: Slight anemia was found in peripheral blood. In the coagulation test, prothrombin time, thrombin time, and hepaplastin time were 65%, 56%, and 65%, respectively. Serum levels ofhepatic enzyme such as GOT,GPT, LDHwere normal. Serum levels of biliary enzyme such as ALP, LAP, 7GT were slightly elevated. (normal: 4.6-12.6 jjig/dl), 1.5 pg/ml (normal: 3.0-5.8 pg/ml), and 0.67 ng/dl (normal: 0.85-2. 15 ng/dl), respectively. Serum thyrotropin (TSH) levels were 6.8 |aU/ml (normal: 0.6-5. 1 jllU/ ml). Serum reverse T3 , thyroxine-binding globulin (TBG), and TSH receptor antibody (TR-Ab) levels were as follows: 3 10 pg/ ml (normal: 190-375 pg/ml), 15 jug/ml (normal: 14-28 jag/ml), and 1.8% (normal: below 15%), respectively. 123I uptake was low (4%). Thyroid test and microsome test were negative. The baseline levels of other hormones were within normal limits. Serum TSHresponse, measured by Sucrosep TSHkit (Special Reference Lab, Tokyo), to a single intravenous (iv) injection of thyrotropin-releasing hormone (TRH) (500 |Lig) was exaggerated as shown in Fig. 1 induced hypoglycemia (regular insulin 0.1 U/kg, iv) were normal ( Figs. 1-3) . Unexpectedly, serum growth hormone (GH) response, measured by Sucrocep GHkit (SRL), to insulin-induced hypoglycemia (regular insulin 0. 1 U/kg, iv) was extensively exaggerated (Fig. 3) . While, serum somatomedin C levels was 1.25 U/ml (normal: 0.36-2.00 U/ml). All hormonal responses to provocation tests described above showeda somewhat delayed pattern.
Endomyocardial biopsy specimens taken from the left ventricle demonstrated irregular hypertrophy and uniform perinuclear vacuolization. Renal biopsy specimens showed multiple vacuoles in the epithelial cells of the parietal and visceral layers of Bowman's capsule, and marked tubulointerstitial fibrosis. And fibrosis of the endothelial cells of renal blood vessels was also observed to some extent. Thyroid biopsy specimens showed slightly atrophic thyroidal tissue (Fig.4) .
Some of these pathological findings were thought to be compatible with Fabry disease. Therefore, oc-galactosidase activity in the leucocytes of this patient was examined. The ocgalactosidase activity of the leucocytes of this patient was markedly decreased (1.9 nmol/mg/h, normal: 25. 1-55.4 nmol/ mg/h), however those of the brother and sister of this patient were normal (47.5 nmol/mg/h, 37.2 nmol/mg/h, respectively). Thin layer chromatography of lipid extract of urinary sediments revealed excessive excretion of CTHand CDHin the patient and his sister (Fig. 5) . Furthermore, thin layer chromatography of lipid extracts of the kidney and the thyroid gland of this patient obtained by biopsy also revealed excessive excretion of CTHand CDH (Fig. 6 ). Based on these findings, the patient was diagnosed as a hemizygote of Fabry disease, and his sister was assumed to be a heterozygous carrier of Fabry disease. 
Discussion
Clinically, the metabolic abnormality becomes manifest during childhood or adolescence in the hemizygous male of Fabry disease. But rare variants have been described with milder manifestations of the disease (4, (10) (11) (12) (13) (14) (15) . In contrast to the typical patients, who have essentially no detectable agalactosidase activity, biochemical investigation of these variants has revealed the presence of residual oc-galactosidase activity, consistent with the attenuation or absence of the characteristic clinical manifestations.
The patient reported here differs from those with classic Fabry disease in several respects. In this patient, some of the typical manifestations of Fabry disease such as angiokeratoma and acroparesthesia were absent. The diagnosis of Fabry disease in this case was first considered on examination of materials obtained by endomyocardial biopsy. Although direct analysis of the biopsy materials was not undertaken, oc-galactosidase On the other hand, endocrinological evaluations in this patient revealed low levels of serum thyroid hormones and high TSHlevels which showed an exaggerated response to TRH (500 jig, iv), suggesting that this patient had primary hypothyroidism.
Furthermore, thin layer chromatography of the lipid extract of the thyroid gland of this patient revealed excessive excretion of CTHand CDH.In consideration of these findings, it is possible to speculate that hypothyroidism present in this patient may be caused by the accumulation of CTHand CDH.Unexpectedly, serum GHlevels showed a marked exaggerated response to insulin-induced hypoglycemia (regular insulin 0.1 U/kg, iv). The exaggerated GHresponse could be induced by impaired synthesis of somatomedin C in the liver. But in this patient, the serum level of hepatic enzyme and somatomedin C level were normal. Thus, this possibility seems to be unlikely. GH secretion is under the control of two hypothalamic peptides, GH-releasing factor (GRF) and somatostatin (16) . GRF stimulates GH secretion, while somatostatin inhibits GHsecretion. Particularly, somatostatin has an important role in the tonic inhibitory control ofbasal GH levels, and when the inhibitory somatostatinergic component is inactivated, GHresponse to the usual provocative stimuli are moreexuberant. Therefore it is also feasible to speculate that the secretory mechanism of somatostatin in the anterior hypothalamic periventricular system may be impaired, possibly by the accumulation of CTHand CDH,although the basal GHlevels were not elevated. In addition, all hormonal responses to various provocation tests showeda somewhat delayed pattern, also suggestive ofhypothalamic disorders. Thus, several endocrine disorders were observed in this patient, and the cause of the disorders may be attributed to Fabry disease. To date an endocrine disorder, particularly thyroid dysfunction has never been reported in Fabry disease. Therefore, the case described here seems to be quite interesting.
